ibi310
mAbexperimental
Clinical trial activity
15 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
10
Phase 3
2
Phase 4
0
Earliest trial started Sep 14, 2018 (NCT03545971)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Melanoma · Phase 3
- Microsatellite Instability · Phase 2
- Nasopharyngeal Carcinoma · Phase 1/Phase 2
- Neoplasms · Phase 2
- Stomach Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06620822 | Phase 2 | Sep 30, 2024 | Huazhong University of Science and Technology |
| NCT06580574 | Phase 2 | Aug 13, 2024 | Peking University |
| NCT05890742 | Phase 1 | May 25, 2023 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05653180 | Phase 1/Phase 2 (Phase 2) | Jan 19, 2023 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05363722 | Phase 1 | May 31, 2022 | Fudan University |
| NCT05165407 | Phase 2 | Mar 31, 2022 | Chinese Academy of Medical Sciences, Peking University |
| NCT05118334 | Phase 1 | Nov 12, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04945421 | Phase 1/Phase 2 (Phase 2) | Jul 23, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04868760 | Phase 1 | Jun 4, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04720716 | Phase 3 | Feb 7, 2021 | Fudan University, Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04590599 | Phase 2 | Dec 8, 2020 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04277663 | Phase 3 | Mar 31, 2020 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04258111 | Phase 2 | Feb 29, 2020 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04202601 | Phase 1/Phase 2 (Phase 2) | Dec 13, 2019 | Innovent Biologics (Suzhou) Co. Ltd., Peking University |
| NCT03545971 | Phase 1 | Sep 14, 2018 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 11 | 10 | 3 | 2018 |
| Peking University | Academic/Hospital | 3 | 3 | 1 | 2019 |
| Fudan University | Academic/Hospital | 2 | 1 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1